There has been an accumulation of evidence in recent years to demonstrate that surgical treatment is more effective than eyedrops at lowering intraocular pressure and preserving the visual field in primary open angle glaucoma.' 2 The argument against primary surgery for glaucoma has been the risk to the eye of performing an intraocular operation. Respiratory and cardiovascular disease are also common in this age group and both may be affected by eyedrops prescribed for glaucoma.
glaucoma.' 2 The argument against primary surgery for glaucoma has been the risk to the eye of performing an intraocular operation. The risks of topical medical therapy to general health, particularly that of elderly people, have been underestimated and surgery is likely to be both a safer and a more effective option for patients requiring treatment for glaucoma.
The only therapeutic approach to have proved effective in glaucoma is lowering intraocular pressure. Eyedrops are the mainstay of glaucoma treatment and, because they are excellent ocular hypotensives with few local side effects, topical 1 antagonists are the class of drug most often prescribed.3 Therapy is life long and many people of extreme old age receive treatment.
Ophthalmologists and geriatricians have many patients in common. Open angle glaucoma is predominantly a disease of old age, affecting up to 5% of the population by 65 years and becoming even more common in older age. 4 5 Respiratory and cardiovascular disease are also common in this age group and both may be affected by eyedrops prescribed for glaucoma.
Topical 1 antagonists
There are two main classes of 1 adrenergic antagonists; non-selective, which affect both 13 receptors, found predominantly in the heart, and 12 receptors, found in the lungs. Timolol, cartelol, and levobunalol are non-selective preparations. Cardioselective 1 antagonists bind to 13 receptors preferentially and have relatively less effect on 12 receptors. Respiratory side effects are less common with cardioselective preparations but they may still occur and they should be avoided in patients with airways obstruction.
Side effects of treatment with oral 1 antagonists include heart failure, hypotension, and bronchospasm.
The same side effects occur with topical therapy.6 7 Drugs administered topically to the eye gain access to the systemic circulation via the nasolacrimal duct and the nasal mucosa. This avoids first pass metabolism by the liver and significant amounts of topically administered drugs may be absorbed into the systemic circulation. For example, two drops of a 0 5% timolol solution, one to each eye, can approximate to the 10 mg oral dose given to treat systemic hypertension or angina. The first study, recently published in the Lancet, recorded nges in spirometry, an exercise walk tolerance test and measurement of blood pressure, and resting and exercise pulse.'8 Eighty patients, aged over 60 years, without history of airways disease, using timolol for at least 1 year, were recruited into a randomised, double masked, crossover study changing therapy to betaxolol or dipivefrine. The study comprised two phases and all patients who completed both phases underwent a change in therapy. Third party randomisation produced four groups: TTB (timolol-timolol-betaxolol); TTD (timolol-timololdipivefrine); TBT (timolol-betaxolol-timolol); and TDT (timolol-dipivefrine-timolol). During phase I, group TBT was allocated to receive one drop to both eyes of 05°/o betaxolol and group TDT one drop of 0 1% dipivefrine twice daily for four weeks. Groups TTB and l-lTD continued to receive topical timolol for four weeks. In the second phase, groups TBT and TDT returned to timolol while group TTB was allocated to receive one drop to both eyes of 0-/5% betaxolol and group TTD one drop of 0 1% dipivefrine twice daily for 4 weeks. Outcome measures were recorded on enrolment and at the end of each phase. The study design allowed comparisons between treatment change and controls as well as treatment change and return to original therapy (Table 1) . (6) 75 (11) 75 (8) 75 (8) Phase I 76 (5) 74 (7) 78 (7) 82 (16) Phase II 77 (7) 75 (8) 75 (8) 75 (8) Walk distance (metres) Enrolment 176 (51) 170 (59) 181 (36) 188 ( Changing from timolol to dipivefrine or betaxolol was associated with significant increase in mean resting and exercise pulse ( Table 2 ). The reduced exercise tachycardia with timolol may contribute to the shorter mean distance walked by patients with timolol (Table 1) . Topical timolol was acting as a systemic hypotensive agent. Mean systolic and diastolic blood pressures were also lower with timolol than with dipivefrine or betaxolol ( Of particular concern is the high (26% in the first and 40% in the second) proportion of patients demonstrating clinically significant reversible airflow tract obstruction. It is important that such people be identified because they are liable to develop severe bronchospasm, especially if they contract a respiratory tract infection. Because of this risk, therapy with 3 antagonists is contraindicated in such patients, even if they are asymptomatic.
Both studies attempted, by using a standard symptom inquiry and the spirometric response to nebulised salbutamol, to identify patients who would show reversible airflow tract obstruction, in advance of change in therapy. Unfortunately, even using such predictors, some asymptomatic patients experiencing clinically significant airflow obstruction would be missed. The studies suggest more than a quarter of those receiving timolol, apparently without complication, should not be and there is no method of identifying them. In clinical practice the proportion is likely to be higher because of the strict entry criteria that were used in these studies. Effectiveness of punctal occlusion It has been suggested that occlusion of the tear punctum for 5 minutes reduces by 67% the amount of topically applied timolol reaching the systemic circulation. 30 Occlusion of the tear duct, especially for such a long time, is a difficult manoeuvre for elderly people to perform and few are likely to comply. In the study by Diggory et al, 18 19 out of 80 patients enrolled claimed to occlude their tear punctum, but no statistically significant (Mann-Whitney) differences between enrolment and review values of spirometry, blood pressure, resting or exercise pulse were found between those who claimed to occlude their punctum after instillation and those who did not (Table 3) . Systemic delivery of topically applied drugs must be assumed to occur.
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Alternative medication Using cardioselective ,B antagonists reduces the risk of respiratory impairment, but the risks of cardiovascular problems associated with other antagonists, such as falls, still exist. Betaxolol is a less effective ocular hypotensive agent than timolol (Table 1 ) and combination rather than single therapy may be required. Other ,B antagonists are non-selective and likely to have the same respiratory and cardiovascular side effects as timolol.
The cholinergic agonist pilocarpine, administered topically, lowers intraocular pressure but has unpleasant local side effects. Systemic absorption can cause gastrointestinal side effects and confusion.3' The local side effects and four times daily dosage, make it unpopular therapy with patients and many comply poorly.32 Pilocarpine is an excellent ocular hypotensive agent; long acting and slow release formulations are available and their more widespread use should be considered.
Topical adrenaline and dipivefrine are commonly used second line drugs. They are less effective than antagonists at lowering intraocular pressure and have more ocular side effects, particularly red eye and follicular conjunctivitis. Their long term use has been shown to make subsequent drainage surgery more likely to fail from fibrosis.33 This has led some eye departments to remove sympathomimetics from their formulary. As with the withdrawal of the antagonist metipranolol, for causing uveitis in a small field deterioration was also less in the surgery group but, because of the methods of visual field analysis used and the lack of universally accepted criteria for assessing visual field change, the results were not as convincing in showing a beneficial effect on visual field survival for patients undergoing trabeculectomy as might be hoped. Ideas as to the desired level of intraocular pressure reduction are changing. No longer is a intraocular pressure of 21 mm Hg or less considered satisfactory for all glaucoma patients, but a 'target pressure' for each patient should be set; for example, for eyes with severe field loss, an intraocular pressure of 15 mm Hg or less is more appropriate.36 Surgery may be the only way to achieve this and this has led some North American glaucoma specialists, traditionally resistant to early surgical treatment of glaucoma, to undertake a prospective study of primary trabeculectomy. The Moorfields primary treatment trial patients were white, predominantly elderly, and had had no previous intraocular surgery, and could be expected to have a high success rate with surgery -only one failure was reported. Prior medical therapy prejudices the outcome of subsequent drainage surgery by promoting fibroblast activity and subsequent scarring of the drainage bleb.37 Young patients and Africans patients also have a poor success rate and antiproliferative agents such as 5-fluorouracil and mitomycin C are commonly used for these cases.
Whether the use of antiproliferative agents at the time of trabeculectomy does lower intraocular pressure and enhance visual field survival in all patients undergoing trabeculectomy, will be addressed by the Moorfields 5-fluorouracil trial.
Trabeculectomy can be performed as a day-case procedure under local anaesthesia, either with local infiltration, retrobulbar, or peribulbar anaesthetic38 avoiding the risks of general anaesthesia. 
